Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 15 entries
Sorted by: Best Match Show Resources per page
A second-generation micro/nano capsules of an endogenous primary un-metabolised bile acid, stabilized by Eudragit-alginate complex with antioxidant compounds.

Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society

Mooranian A, Zamani N, Mikov M, Goločorbin-Kon S, Stojanovic G, Arfuso F, Kovacevic B, Al-Salami H.
PMID: 32042255
Saudi Pharm J. 2020 Feb;28(2):165-171. doi: 10.1016/j.jsps.2019.11.017. Epub 2019 Dec 07.

Bile acids (BAs) are amphiphilic compounds and of recently have demonstrated wide range of formulation stabilizing effects. A recent study showed that primary un-metabolised bile acids (PUBAs) have β-cell protective effects, and synergistic antidiabetic effects when combined with antioxidant...

Cite
Mooranian A, Zamani N, Mikov M, et al. A second-generation micro/nano capsules of an endogenous primary un-metabolised bile acid, stabilized by Eudragit-alginate complex with antioxidant compounds. Saudi Pharm J. 2019;28(2):165-171doi: 10.1016/j.jsps.2019.11.017.
Mooranian, A., Zamani, N., Mikov, M., Goločorbin-Kon, S., Stojanovic, G., Arfuso, F., Kovacevic, B., & Al-Salami, H. (2020). A second-generation micro/nano capsules of an endogenous primary un-metabolised bile acid, stabilized by Eudragit-alginate complex with antioxidant compounds. Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society, 28(2), 165-171. https://doi.org/10.1016/j.jsps.2019.11.017
Mooranian, Armin, et al. "A second-generation micro/nano capsules of an endogenous primary un-metabolised bile acid, stabilized by Eudragit-alginate complex with antioxidant compounds." Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society vol. 28,2 (2020): 165-171. doi: https://doi.org/10.1016/j.jsps.2019.11.017
Mooranian A, Zamani N, Mikov M, Goločorbin-Kon S, Stojanovic G, Arfuso F, Kovacevic B, Al-Salami H. A second-generation micro/nano capsules of an endogenous primary un-metabolised bile acid, stabilized by Eudragit-alginate complex with antioxidant compounds. Saudi Pharm J. 2020 Feb;28(2):165-171. doi: 10.1016/j.jsps.2019.11.017. Epub 2019 Dec 07. PMID: 32042255; PMCID: PMC7000308.
Copy Download .nbib Format: NLM
Pharmacological Applications of Bile Acids and Their Derivatives in the Treatment of Metabolic Syndrome.

Frontiers in pharmacology

Ðanić M, Stanimirov B, Pavlović N, Goločorbin-Kon S, Al-Salami H, Stankov K, Mikov M.
PMID: 30559664
Front Pharmacol. 2018 Dec 03;9:1382. doi: 10.3389/fphar.2018.01382. eCollection 2018.

Apart from well-known functions of bile acids in digestion and solubilization of lipophilic nutrients and drugs in the small intestine, the emerging evidence from the past two decades identified the role of bile acids as signaling, endocrine molecules that...

Cite
Ðanić M, Stanimirov B, Pavlović N, et al. Pharmacological Applications of Bile Acids and Their Derivatives in the Treatment of Metabolic Syndrome. Front Pharmacol. 2018;9:1382doi: 10.3389/fphar.2018.01382.
Ðanić, M., Stanimirov, B., Pavlović, N., Goločorbin-Kon, S., Al-Salami, H., Stankov, K., & Mikov, M. (2018). Pharmacological Applications of Bile Acids and Their Derivatives in the Treatment of Metabolic Syndrome. Frontiers in pharmacology, 91382. https://doi.org/10.3389/fphar.2018.01382
Ðanić, Maja, et al. "Pharmacological Applications of Bile Acids and Their Derivatives in the Treatment of Metabolic Syndrome." Frontiers in pharmacology vol. 9 (2018): 1382. doi: https://doi.org/10.3389/fphar.2018.01382
Ðanić M, Stanimirov B, Pavlović N, Goločorbin-Kon S, Al-Salami H, Stankov K, Mikov M. Pharmacological Applications of Bile Acids and Their Derivatives in the Treatment of Metabolic Syndrome. Front Pharmacol. 2018 Dec 03;9:1382. doi: 10.3389/fphar.2018.01382. eCollection 2018. PMID: 30559664; PMCID: PMC6287190.
Copy Download .nbib Format: NLM
Bile Acids and Their Derivatives as Potential Modifiers of Drug Release and Pharmacokinetic Profiles.

Frontiers in pharmacology

Pavlović N, Goločorbin-Kon S, Ðanić M, Stanimirov B, Al-Salami H, Stankov K, Mikov M.
PMID: 30467479
Front Pharmacol. 2018 Nov 08;9:1283. doi: 10.3389/fphar.2018.01283. eCollection 2018.

Bile acids have received considerable interest in the drug delivery research due to their peculiar physicochemical properties and biocompatibility. The main advantage of bile acids as drug absorption enhancers is their ability to act as both drug solubilizing and...

Cite
Pavlović N, Goločorbin-Kon S, Ðanić M, et al. Bile Acids and Their Derivatives as Potential Modifiers of Drug Release and Pharmacokinetic Profiles. Front Pharmacol. 2018;9:1283doi: 10.3389/fphar.2018.01283.
Pavlović, N., Goločorbin-Kon, S., Ðanić, M., Stanimirov, B., Al-Salami, H., Stankov, K., & Mikov, M. (2018). Bile Acids and Their Derivatives as Potential Modifiers of Drug Release and Pharmacokinetic Profiles. Frontiers in pharmacology, 91283. https://doi.org/10.3389/fphar.2018.01283
Pavlović, Nebojša, et al. "Bile Acids and Their Derivatives as Potential Modifiers of Drug Release and Pharmacokinetic Profiles." Frontiers in pharmacology vol. 9 (2018): 1283. doi: https://doi.org/10.3389/fphar.2018.01283
Pavlović N, Goločorbin-Kon S, Ðanić M, Stanimirov B, Al-Salami H, Stankov K, Mikov M. Bile Acids and Their Derivatives as Potential Modifiers of Drug Release and Pharmacokinetic Profiles. Front Pharmacol. 2018 Nov 08;9:1283. doi: 10.3389/fphar.2018.01283. eCollection 2018. PMID: 30467479; PMCID: PMC6237018.
Copy Download .nbib Format: NLM
Probucol-poly(meth)acrylate-bile acid nanoparticles increase IL-10, and primary bile acids in prediabetic mice.

Therapeutic delivery

Mooranian A, Zamani N, Takechi R, Al-Sallami H, Mikov M, Goločorbin-Kon S, Kovacevic B, Arfuso F, Al-Salami H.
PMID: 31646943
Ther Deliv. 2019 Oct 24; doi: 10.4155/tde-2019-0052. Epub 2019 Oct 24.

No abstract available.

Cite
Mooranian A, Zamani N, Takechi R, et al. Probucol-poly(meth)acrylate-bile acid nanoparticles increase IL-10, and primary bile acids in prediabetic mice. Ther Deliv. 2019;doi: 10.4155/tde-2019-0052.
Mooranian, A., Zamani, N., Takechi, R., Al-Sallami, H., Mikov, M., Goločorbin-Kon, S., Kovacevic, B., Arfuso, F., & Al-Salami, H. (2019). Probucol-poly(meth)acrylate-bile acid nanoparticles increase IL-10, and primary bile acids in prediabetic mice. Therapeutic delivery, . https://doi.org/10.4155/tde-2019-0052
Mooranian, Armin, et al. "Probucol-poly(meth)acrylate-bile acid nanoparticles increase IL-10, and primary bile acids in prediabetic mice." Therapeutic delivery vol. (2019). doi: https://doi.org/10.4155/tde-2019-0052
Mooranian A, Zamani N, Takechi R, Al-Sallami H, Mikov M, Goločorbin-Kon S, Kovacevic B, Arfuso F, Al-Salami H. Probucol-poly(meth)acrylate-bile acid nanoparticles increase IL-10, and primary bile acids in prediabetic mice. Ther Deliv. 2019 Oct 24; doi: 10.4155/tde-2019-0052. Epub 2019 Oct 24. PMID: 31646943.
Copy Download .nbib Format: NLM
Deoxycholic Acid as a Modifier of the Permeation of Gliclazide through the Blood Brain Barrier of a Rat.

Journal of diabetes research

Lalić-Popović M, Vasović V, Milijašević B, Goločorbin-Kon S, Al-Salami H, Mikov M.
PMID: 23671878
J Diabetes Res. 2013;2013:598603. doi: 10.1155/2013/598603. Epub 2013 Mar 13.

Major problem for diabetic patients represents damage of blood vessels and the oxidative stress of the brain cells due to increased concentration of free radicals and poor nutrition of brain cells. Gliclazide has antioxidative properties and poor blood brain...

Cite
Lalić-Popović M, Vasović V, Milijašević B, et al. Deoxycholic Acid as a Modifier of the Permeation of Gliclazide through the Blood Brain Barrier of a Rat. J Diabetes Res. 2013;2013:598603doi: 10.1155/2013/598603.
Lalić-Popović, M., Vasović, V., Milijašević, B., Goločorbin-Kon, S., Al-Salami, H., & Mikov, M. (2013). Deoxycholic Acid as a Modifier of the Permeation of Gliclazide through the Blood Brain Barrier of a Rat. Journal of diabetes research, 2013598603. https://doi.org/10.1155/2013/598603
Lalić-Popović, Mladena, et al. "Deoxycholic Acid as a Modifier of the Permeation of Gliclazide through the Blood Brain Barrier of a Rat." Journal of diabetes research vol. 2013 (2013): 598603. doi: https://doi.org/10.1155/2013/598603
Lalić-Popović M, Vasović V, Milijašević B, Goločorbin-Kon S, Al-Salami H, Mikov M. Deoxycholic Acid as a Modifier of the Permeation of Gliclazide through the Blood Brain Barrier of a Rat. J Diabetes Res. 2013;2013:598603. doi: 10.1155/2013/598603. Epub 2013 Mar 13. PMID: 23671878; PMCID: PMC3647598.
Copy Download .nbib Format: NLM
Stability and Release Kinetics of an Advanced Gliclazide-Cholic Acid Formulation: The Use of Artificial-Cell Microencapsulation in Slow Release Targeted Oral Delivery of Antidiabetics.

Journal of pharmaceutical innovation

Mooranian A, Negrulj R, Mathavan S, Martinez J, Sciarretta J, Chen-Tan N, Mukkur T, Mikov M, Lalic-Popovic M, Stojančević M, Golocorbin-Kon S, Al-Salami H.
PMID: 24829616
J Pharm Innov. 2014;9:150-157. doi: 10.1007/s12247-014-9182-5.

INTRODUCTION: In previous studies carried out in our laboratory, a bile acid (BA) formulation exerted a hypoglycaemic effect in a rat model of type-1 diabetes (T1D). When the antidiabetic drug gliclazide (G) was added to the bile acid, it...

Cite
Mooranian A, Negrulj R, Mathavan S, et al. Stability and Release Kinetics of an Advanced Gliclazide-Cholic Acid Formulation: The Use of Artificial-Cell Microencapsulation in Slow Release Targeted Oral Delivery of Antidiabetics. J Pharm Innov. 2014;9:150-157doi: 10.1007/s12247-014-9182-5.
Mooranian, A., Negrulj, R., Mathavan, S., Martinez, J., Sciarretta, J., Chen-Tan, N., Mukkur, T., Mikov, M., Lalic-Popovic, M., Stojančević, M., Golocorbin-Kon, S., & Al-Salami, H. (2014). Stability and Release Kinetics of an Advanced Gliclazide-Cholic Acid Formulation: The Use of Artificial-Cell Microencapsulation in Slow Release Targeted Oral Delivery of Antidiabetics. Journal of pharmaceutical innovation, 9150-157. https://doi.org/10.1007/s12247-014-9182-5
Mooranian, Armin, et al. "Stability and Release Kinetics of an Advanced Gliclazide-Cholic Acid Formulation: The Use of Artificial-Cell Microencapsulation in Slow Release Targeted Oral Delivery of Antidiabetics." Journal of pharmaceutical innovation vol. 9 (2014): 150-157. doi: https://doi.org/10.1007/s12247-014-9182-5
Mooranian A, Negrulj R, Mathavan S, Martinez J, Sciarretta J, Chen-Tan N, Mukkur T, Mikov M, Lalic-Popovic M, Stojančević M, Golocorbin-Kon S, Al-Salami H. Stability and Release Kinetics of an Advanced Gliclazide-Cholic Acid Formulation: The Use of Artificial-Cell Microencapsulation in Slow Release Targeted Oral Delivery of Antidiabetics. J Pharm Innov. 2014;9:150-157. doi: 10.1007/s12247-014-9182-5. PMID: 24829616; PMCID: PMC4013442.
Copy Download .nbib Format: NLM
Bio Micro-Nano Technologies of Antioxidants Optimised Their Pharmacological and Cellular Effects, ex vivo, in Pancreatic β-Cells.

Nanotechnology, science and applications

Mooranian A, Zamani N, Mikov M, Goločorbin-Kon S, Stojanovic G, Arfuso F, Kovacevic B, Al-Salami H.
PMID: 32021126
Nanotechnol Sci Appl. 2020 Jan 07;13:1-9. doi: 10.2147/NSA.S212323. eCollection 2020.

INTRODUCTION: Recent formulation and microencapsulation studies of probucol (PB) using the polymer sodium alginate (SA) and bile acids have shown promising results but PB stability, and pharmacology profiles remain suboptimal. This study aimed to investigate novel polymers for the...

Cite
Mooranian A, Zamani N, Mikov M, et al. Bio Micro-Nano Technologies of Antioxidants Optimised Their Pharmacological and Cellular Effects, ex vivo, in Pancreatic β-Cells. Nanotechnol Sci Appl. 2020;13:1-9doi: 10.2147/NSA.S212323.
Mooranian, A., Zamani, N., Mikov, M., Goločorbin-Kon, S., Stojanovic, G., Arfuso, F., Kovacevic, B., & Al-Salami, H. (2020). Bio Micro-Nano Technologies of Antioxidants Optimised Their Pharmacological and Cellular Effects, ex vivo, in Pancreatic β-Cells. Nanotechnology, science and applications, 131-9. https://doi.org/10.2147/NSA.S212323
Mooranian, Armin, et al. "Bio Micro-Nano Technologies of Antioxidants Optimised Their Pharmacological and Cellular Effects, ex vivo, in Pancreatic β-Cells." Nanotechnology, science and applications vol. 13 (2020): 1-9. doi: https://doi.org/10.2147/NSA.S212323
Mooranian A, Zamani N, Mikov M, Goločorbin-Kon S, Stojanovic G, Arfuso F, Kovacevic B, Al-Salami H. Bio Micro-Nano Technologies of Antioxidants Optimised Their Pharmacological and Cellular Effects, ex vivo, in Pancreatic β-Cells. Nanotechnol Sci Appl. 2020 Jan 07;13:1-9. doi: 10.2147/NSA.S212323. eCollection 2020. PMID: 32021126; PMCID: PMC6954832.
Copy Download .nbib Format: NLM
Plasma Distribution of Methotrexate and Its Polyglutamates in Pediatric Acute Lymphoblastic Leukemia: Preliminary Insights.

European journal of drug metabolism and pharmacokinetics

Rajšić I, Lazarević S, Đanić M, Al-Salami H, Mooranian A, Vukmirović S, Mikov M, Goločorbin-Kon S.
PMID: 34637107
Eur J Drug Metab Pharmacokinet. 2022 Jan;47(1):127-134. doi: 10.1007/s13318-021-00726-9. Epub 2021 Oct 12.

BACKGROUND AND OBJECTIVE: High-dose methotrexate (HD-MTX) is the mainstream therapy of current acute lymphoblastic leukemia (ALL) regimens, but frequent intra- and interindividual differences in the clinical response to HD-MTX lead to chemotherapeutic interruption or discontinuation. The exact mechanism of...

Cite
Rajšić I, Lazarević S, Đanić M, et al. Plasma Distribution of Methotrexate and Its Polyglutamates in Pediatric Acute Lymphoblastic Leukemia: Preliminary Insights. Eur J Drug Metab Pharmacokinet. 2021;47(1):127-134doi: 10.1007/s13318-021-00726-9.
Rajšić, I., Lazarević, S., Đanić, M., Al-Salami, H., Mooranian, A., Vukmirović, S., Mikov, M., & Goločorbin-Kon, S. (2022). Plasma Distribution of Methotrexate and Its Polyglutamates in Pediatric Acute Lymphoblastic Leukemia: Preliminary Insights. European journal of drug metabolism and pharmacokinetics, 47(1), 127-134. https://doi.org/10.1007/s13318-021-00726-9
Rajšić, Ivana, et al. "Plasma Distribution of Methotrexate and Its Polyglutamates in Pediatric Acute Lymphoblastic Leukemia: Preliminary Insights." European journal of drug metabolism and pharmacokinetics vol. 47,1 (2022): 127-134. doi: https://doi.org/10.1007/s13318-021-00726-9
Rajšić I, Lazarević S, Đanić M, Al-Salami H, Mooranian A, Vukmirović S, Mikov M, Goločorbin-Kon S. Plasma Distribution of Methotrexate and Its Polyglutamates in Pediatric Acute Lymphoblastic Leukemia: Preliminary Insights. Eur J Drug Metab Pharmacokinet. 2022 Jan;47(1):127-134. doi: 10.1007/s13318-021-00726-9. Epub 2021 Oct 12. PMID: 34637107.
Copy Download .nbib Format: NLM
Pharmacological effects of novel microvesicles of basil, on blood glucose and the lipid profile: a preclinical study.

Scientific reports

Teofilovic B, Golocorbin-Kon S, Stilinovic N, Grujic-Letic N, Raškovic A, Mooranian A, Al-Salami H, Mikov M.
PMID: 34764416
Sci Rep. 2021 Nov 11;11(1):22123. doi: 10.1038/s41598-021-01713-5.

Microencapsulation represents a process that can create targeted, controlled release kinetics of drugs, thus optimizing therapeutic efficacy. Our group has investigated the impact of this technology on Wistar rats to determine pharmacological efficacy of basil extracts. Animals were treated...

Cite
Teofilovic B, Golocorbin-Kon S, Stilinovic N, et al. Pharmacological effects of novel microvesicles of basil, on blood glucose and the lipid profile: a preclinical study. Sci Rep. 2021;11(1):22123doi: 10.1038/s41598-021-01713-5.
Teofilovic, B., Golocorbin-Kon, S., Stilinovic, N., Grujic-Letic, N., Raškovic, A., Mooranian, A., Al-Salami, H., & Mikov, M. (2021). Pharmacological effects of novel microvesicles of basil, on blood glucose and the lipid profile: a preclinical study. Scientific reports, 11(1), 22123. https://doi.org/10.1038/s41598-021-01713-5
Teofilovic, Branislava, et al. "Pharmacological effects of novel microvesicles of basil, on blood glucose and the lipid profile: a preclinical study." Scientific reports vol. 11,1 (2021): 22123. doi: https://doi.org/10.1038/s41598-021-01713-5
Teofilovic B, Golocorbin-Kon S, Stilinovic N, Grujic-Letic N, Raškovic A, Mooranian A, Al-Salami H, Mikov M. Pharmacological effects of novel microvesicles of basil, on blood glucose and the lipid profile: a preclinical study. Sci Rep. 2021 Nov 11;11(1):22123. doi: 10.1038/s41598-021-01713-5. PMID: 34764416; PMCID: PMC8586354.
Copy Download .nbib Format: NLM
Formulation buoyancy of nanoencapsulated gliclazide using primary, conjugated and deconjugated bile acids.

Therapeutic delivery

Mathavan S, Ionescu CM, Kovacevic B, Mikov M, Golocorbin-Kon S, Mooranian A, Dass CR, Al-Salami H.
PMID: 31646950
Ther Deliv. 2019 Oct 24; doi: 10.4155/tde-2019-0058. Epub 2019 Oct 24.

No abstract available.

Cite
Mathavan S, Ionescu CM, Kovacevic B, et al. Formulation buoyancy of nanoencapsulated gliclazide using primary, conjugated and deconjugated bile acids. Ther Deliv. 2019;doi: 10.4155/tde-2019-0058.
Mathavan, S., Ionescu, C. M., Kovacevic, B., Mikov, M., Golocorbin-Kon, S., Mooranian, A., Dass, C. R., & Al-Salami, H. (2019). Formulation buoyancy of nanoencapsulated gliclazide using primary, conjugated and deconjugated bile acids. Therapeutic delivery, . https://doi.org/10.4155/tde-2019-0058
Mathavan, Sangeetha, et al. "Formulation buoyancy of nanoencapsulated gliclazide using primary, conjugated and deconjugated bile acids." Therapeutic delivery vol. (2019). doi: https://doi.org/10.4155/tde-2019-0058
Mathavan S, Ionescu CM, Kovacevic B, Mikov M, Golocorbin-Kon S, Mooranian A, Dass CR, Al-Salami H. Formulation buoyancy of nanoencapsulated gliclazide using primary, conjugated and deconjugated bile acids. Ther Deliv. 2019 Oct 24; doi: 10.4155/tde-2019-0058. Epub 2019 Oct 24. PMID: 31646950.
Copy Download .nbib Format: NLM
Probiotic Pre-treatment Reduces Gliclazide Permeation (ex vivo) in Healthy Rats but Increases It in Diabetic Rats to the Level Seen in Untreated Healthy Rats.

Archives of drug information

Al-Salami H, Butt G, Tucker I, Skrbic R, Golocorbin-Kon S, Mikov M.
PMID: 20157366
Arch Drug Inf. 2008 Jul;1(1):35-41. doi: 10.1111/j.1753-5174.2008.00006.x.

AIM: To investigate the influence of probiotic pre-treatment on the permeation of the antidiabetic drug gliclazide in healthy and diabetic rats. METHODS: Wistar rats (age 2-3 months, weight 350 +/- 50 g) were randomly allocated into one of 4...

Cite
Al-Salami H, Butt G, Tucker I, et al. Probiotic Pre-treatment Reduces Gliclazide Permeation (ex vivo) in Healthy Rats but Increases It in Diabetic Rats to the Level Seen in Untreated Healthy Rats. Arch Drug Inf. 2008;1(1):35-41doi: 10.1111/j.1753-5174.2008.00006.x.
Al-Salami, H., Butt, G., Tucker, I., Skrbic, R., Golocorbin-Kon, S., & Mikov, M. (2008). Probiotic Pre-treatment Reduces Gliclazide Permeation (ex vivo) in Healthy Rats but Increases It in Diabetic Rats to the Level Seen in Untreated Healthy Rats. Archives of drug information, 1(1), 35-41. https://doi.org/10.1111/j.1753-5174.2008.00006.x
Al-Salami, Hani, et al. "Probiotic Pre-treatment Reduces Gliclazide Permeation (ex vivo) in Healthy Rats but Increases It in Diabetic Rats to the Level Seen in Untreated Healthy Rats." Archives of drug information vol. 1,1 (2008): 35-41. doi: https://doi.org/10.1111/j.1753-5174.2008.00006.x
Al-Salami H, Butt G, Tucker I, Skrbic R, Golocorbin-Kon S, Mikov M. Probiotic Pre-treatment Reduces Gliclazide Permeation (ex vivo) in Healthy Rats but Increases It in Diabetic Rats to the Level Seen in Untreated Healthy Rats. Arch Drug Inf. 2008 Jul;1(1):35-41. doi: 10.1111/j.1753-5174.2008.00006.x. PMID: 20157366; PMCID: PMC2817444.
Copy Download .nbib Format: NLM
Pharmacological effects of novel microvesicles of basil, on blood glucose and the lipid profile: a preclinical study.

Scientific reports

Teofilovic B, Golocorbin-Kon S, Stilinovic N, Grujic-Letic N, Raškovic A, Mooranian A, Al-Salami H, Mikov M.
PMID: 34764416
Sci Rep. 2021 Nov 11;11(1):22123. doi: 10.1038/s41598-021-01713-5.

Microencapsulation represents a process that can create targeted, controlled release kinetics of drugs, thus optimizing therapeutic efficacy. Our group has investigated the impact of this technology on Wistar rats to determine pharmacological efficacy of basil extracts. Animals were treated...

Cite
Teofilovic B, Golocorbin-Kon S, Stilinovic N, et al. Pharmacological effects of novel microvesicles of basil, on blood glucose and the lipid profile: a preclinical study. Sci Rep. 2021;11(1):22123doi: 10.1038/s41598-021-01713-5.
Teofilovic, B., Golocorbin-Kon, S., Stilinovic, N., Grujic-Letic, N., Raškovic, A., Mooranian, A., Al-Salami, H., & Mikov, M. (2021). Pharmacological effects of novel microvesicles of basil, on blood glucose and the lipid profile: a preclinical study. Scientific reports, 11(1), 22123. https://doi.org/10.1038/s41598-021-01713-5
Teofilovic, Branislava, et al. "Pharmacological effects of novel microvesicles of basil, on blood glucose and the lipid profile: a preclinical study." Scientific reports vol. 11,1 (2021): 22123. doi: https://doi.org/10.1038/s41598-021-01713-5
Teofilovic B, Golocorbin-Kon S, Stilinovic N, Grujic-Letic N, Raškovic A, Mooranian A, Al-Salami H, Mikov M. Pharmacological effects of novel microvesicles of basil, on blood glucose and the lipid profile: a preclinical study. Sci Rep. 2021 Nov 11;11(1):22123. doi: 10.1038/s41598-021-01713-5. PMID: 34764416; PMCID: PMC8586354.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 15 entries